[1]
Zhou, S., Deng, M., Bian, X., Shi, J., Liang, R. and Tao, M. 2024. Synergistic anti-tumor effects of lenalidomide and gefitinib by upregulating ADRB2 and inactivating the mTOR/PI3K/AKT signaling pathway in lung adenocarcinoma: Role of ADRB2 and mTOR/PI3K/AKT in LUAD. Cellular and Molecular Biology. 70, 2 (Feb. 2024), 120–127. DOI:https://doi.org/10.14715/cmb/2024.70.2.17.